Meeting
2013 ASCO Annual Meeting
Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.
Authors
Frans Opdam
Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands
Frans Opdam , Vincent O. Dezentje , Jan den Hartigh , Henk-jan Guchelaar , Trees Hessing , Tahar van der Straaten , Robert Vree , Erdogan Batman , Eduard Maartense , Carolien H. Smorenburg , Anneke Zeillemaker , J. A. C. Brakenhoff , Maartje Los , Philomeen Kuijer , Hein Putter , Anne-Sophie Dieudonné , Patrick Neven , Cornelis J. H. Van De Velde , J. W. R. Nortier , Hans Gelderblom
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NTR1509
Citation
J Clin Oncol 31, 2013 (suppl; abstr 595)
DOI
10.1200/jco.2013.31.15_suppl.595
Abstract #
595
Poster Bd #
8B
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
First Author: Bavanthi Balakrishnar
Poster
2016 ASCO Annual Meeting
Comparison of endoxifen levels between male and female breast cancer patients treated with tamoxifen.
First Author: John Gordon Lenehan
Poster
2016 ASCO Annual Meeting
Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
First Author: Clara Inkyung Lee
Poster
2015 ASCO Annual Meeting
Tamoxifen (TAM)-induced severe hot flashes (HF): Is dose reduction (DR) a safe and effective strategy?
First Author: Clara Inkyung Lee